Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 11/20 | 0.36 |
| ▸ | KDR | P35968 | 11/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033674 | 1.00 | CCR2 (0.53) | CCR2CCR5EPHA2KDRJAK2 | |
| SCHEMBL15033681 | 0.91 | CCR2 (0.52) | CCR2CCR5EPHA2KDRJAK2 | |
| SCHEMBL14318481 | 0.89 | CCR2 (0.50) | CCR2CCR5EPHA2KDRJAK2 | |
| SCHEMBL14318471 | 0.89 | CCR2 (0.50) | CCR2CCR5EPHA2KDRJAK2 | |
| SCHEMBL15033734 | 0.88 | CCR2 (0.63) | CCR2CCR5EPHA2KDREPHB4 | |
| SCHEMBL15033680 | 0.86 | CCR2 (0.40) | CCR2CCR5EGFR | |
| SCHEMBL15033671 | 0.86 | CCR2 (0.40) | CCR2CCR5EGFR | |
| SCHEMBL16257554 | 0.81 | CCR2 (0.63) | CCR2CCR5EPHA2KDRLRRK2 | |
| SCHEMBL16257522 | 0.79 | CCR2 (0.80) | CCR2CCR5EPHA2KDRJAK2 | |
| SCHEMBL16257523 | 0.79 | CCR2 (0.80) | CCR2CCR5EPHA2KDRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721025-B1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | CCR2, CCRL2, CXCR2 | CCR2 1/4885CCR5 6/4885EPHA2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.